The First Clinical Medical College, Nanchang University, Nanchang, 30006, China.
The Department of Respiratory and Critical Care Medicine, Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Mol Biol Rep. 2024 Aug 21;51(1):924. doi: 10.1007/s11033-024-09865-z.
Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor and a member of the ErbB receptor family. As a significant cancer driver, EGFR undergoes mutations such as gene amplification or overexpression in a wide range of malignant tumors and is closely associated with tumorigenesis. This review examines the aberrant expression of EGFR in several common cancers and summarizes the current therapeutic strategies developed for this receptor. Additionally, this review compares the differences in EGFR activation, internalization, endocytosis, and sorting in normal and cancer cells, and highlights some regulatory factors that influence its trafficking process.Kindly check and confirm the edit made in the title.Yes, correctAs per journal instructions structured abstract is mandatory kindly provideThe abstract format does not apply to Review articles.
表皮生长因子受体(EGFR)是一种跨膜酪氨酸激酶受体,也是 ErbB 受体家族的成员。作为一个重要的致癌驱动基因,EGFR 在多种恶性肿瘤中发生基因突变,如基因扩增或过表达,与肿瘤的发生密切相关。本文综述了 EGFR 在几种常见癌症中的异常表达,并总结了针对该受体的现有治疗策略。此外,本文比较了正常细胞和癌细胞中 EGFR 的激活、内化、内吞和分选的差异,并强调了一些影响其运输过程的调节因子。
请检查并确认标题中的编辑。
是的,正确。
根据期刊说明,结构式摘要为必填项,请提供。
摘要格式不适用于综述文章。